Patrick Soon-Shiong is Executive Chairman and CEO of Abraxis Health, which is forging a new paradigm for the delivery of healthcare, requiring a novel global infrastructure, integrating bioinformatics, discovery, molecular medicine and clinical development. Under this model, Abraxis Health will develop, test and validate diagnostics and drugs to target pre-selected patients based on molecular profiles that predict drug response to particular therapeutics. This will enable the delivery of drugs to patients in a predictive, preventative and evidence-based manner, improving outcomes and pharmacoeconomics.

 A noted researcher, physician and surgeon, Patrick is a co-inventor of over 50 issued U.S. patents, has published more than 100 scientific papers, and founded two publicly traded pharmaceutical companies, American Pharma Partners and Abraxis Bioscience, a fully integrated global biotechnology company dedicated to the discovery, development and delivery of next-generation therapeutics and core technologies that offer patients safer and more effective treatments for cancer and other critical illnesses. Pat served as Chairman and CEO of Abraxis Bioscience until April 2009. There, he developed and co-invented the nanoparticle delivery technology known as Abraxane, which is used in the treatment of advanced metastatic breast cancer. Abraxane was launched in 2005 and is now approved in 36 countries. This technology is also being developed for lung, ovarian, prostate, melanoma, head and neck cancers.

In September 2008, Abraxis Bioscience sold its division called APP Pharmaceuticals to Fresenius SE for approximately $3.7 billion. In 2009, Patrick launched Abraxis Health and formed the Chan Soon-Shiong Family Foundation, through which he and his family are focusing on charitable endeavors that will improve healthcare in America and the welfare of its patients. Patrick's vision is to transform healthcare from a qualitative practice of medicine to a quantitative, personalized, predictive, preventive and evidence-based medicine at the point of care at the time of need.

Patrick is on the health advisory board and the President's Council of RAND, where he supported the development of the Comprehensive Assessment of Reform Efforts (COMPARE), recently released by the RAND Corporation. Also in 2009, he was appointed Chairman of the Steering Committee of Life Sciences of the X-Prize Foundation, Board Member of ITA partners, Founding Board Member to Dossia Foundation, Executive Director of the UCLA Wireless Health Institute, and is Professor of Microbiology, Immunology, and Molecular Genetics Professor of Bioengineering at UCLA. In 2008, Patrick received the Medical Visionary Award from the Pancreatic Cancer Action Network. Also notable in his career, Patrick performed the world’s first encapsulated islet transplant in a diabetic patient.